Cartesian Therapeutics, Inc.
RNAC
$8.84
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 43.96% | -94.81% | -92.81% | -97.72% | -98.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.96% | -94.81% | -92.81% | -97.72% | -98.10% |
| Cost of Revenue | 30.88% | 25.54% | 29.24% | 9.63% | 1.55% |
| Gross Profit | -30.62% | -284.72% | -821.85% | -2,699.79% | -2,033.67% |
| SG&A Expenses | 8.72% | 4.40% | 6.58% | -21.71% | -24.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.94% | 17.79% | 20.25% | -4.08% | -9.78% |
| Operating Income | -22.67% | -103.56% | -144.12% | -106.25% | -122.31% |
| Income Before Tax | -347.79% | -323.34% | -80.84% | 81.92% | 85.53% |
| Income Tax Expenses | -3,303.14% | -3,303.14% | -3,303.14% | 101.51% | 101.51% |
| Earnings from Continuing Operations | -318.89% | -296.17% | -68.30% | 80.40% | 84.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -318.89% | -296.17% | -68.30% | 80.40% | 84.21% |
| EBIT | -22.67% | -103.56% | -144.12% | -106.25% | -122.31% |
| EBITDA | -23.28% | -108.02% | -143.68% | -103.97% | -120.47% |
| EPS Basic | -265.88% | -278.54% | 53.03% | 96.36% | 96.89% |
| Normalized Basic EPS | -40.30% | -183.44% | 16.35% | 91.65% | 92.83% |
| EPS Diluted | -264.09% | -270.81% | 53.06% | 96.34% | 96.87% |
| Normalized Diluted EPS | -40.43% | -172.40% | 17.68% | 91.70% | 92.87% |
| Average Basic Shares Outstanding | 9.63% | 17.08% | 50.50% | 111.25% | 203.07% |
| Average Diluted Shares Outstanding | 9.52% | 16.21% | 48.87% | 107.67% | 194.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |